HIV Treatment Bulletin - Vol. 7, No. 6, June 2006
Polly Clayden, HIV i-Base

Previous studies have reported high frequency of sub-optimal nevirapine C_trough levels but no guidelines have suggested a way to manage these patients. Should a clinician confirm the inadequate concentration on another sample because of high intra-patient variability or increase nevirapine dose?

N Machefert from the Centre Hospitalier Universitaire, Toxicologie et Pharmacocinétique, Poitiers, France and coworkers performed a retrospective assessment of the risk of virological failure in a clinical setting for patients having one or more sub-optimal nevirapine C_trough (<3 μg/mL). Additionally, the study was to determine the extent of the intra-patient variability among this group.

The authors evaluated 38 patients receiving standard nevirapine dose as part of their antiretroviral regimen. Nevirapine C_trough concentrations were determined from 245 samples collected at each clinic visit through out the course of their treatment. Viral load and adherence, recorded at each clinic visit, were also evaluated. Virological failure was defined as >1000 copies/mL. The number of patients with one or more C_trough <3 μg/mL were compared to the virological failure group.

Patients received nevirapine for a mean of 700 days; 8/38 patients had virological failure. There were an average of 6 C_trough measurements available per patient. The investigators found 24/ 38 (63%) patients had at least one inadequate C_trough during the course of their treatment. 7/8 (88%) patients had more than one inadequate C_trough in the viral failure group vs 9/30 patients in the group without virological failure, p=0.01. Additionally 6/8 patients in the virological group were considered as non-adherent (confirmed by undetectable plasma concentration measurement during the course of their treatment).

They reported that the intra-individual variability was significant with a mean value of 35% [range: 5-200%] in all patients but only 20% [range: 5-45%] excluding non-adherent patients. The investigators wrote: “This study confirm the high frequency of inadequate C_trough in clinical setting and suggest that only patients exhibiting more than one inadequate NVP C_trough are at risk of virological failure. In routine practice, before nevirapine dosage adjustment, inadequate C_trough should be confirmed and adherence should be assessed.”

Ref: Machefert N, Dupuis A, Le Moal G et al. Relationship between nevirapine concentration and virological failure assessed in a clinical setting. 7th International Workshop on Clinical Pharmacology of HIV Therapy, 20-22 April 2006, Lisbon. Abstract 70.

2006-06-10
IB060706-13

©2006. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.